VISN Stock Before Q4 Earnings: Is it a Smart Buy or Risky Move?

Vistance heads into Q4 earnings after a 294% surge, but macro woes, trade tensions and rich valuation could make this rally a risky bet.

Zacks Investment Research • Feb 23, 2026

Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet

Newtyn Management bought 1.6 million shares of VISN in the fourth quarter. The quarter-end position value was $40.23 million, up from $9.29 million in the previous quarter.

The Motley Fool • Feb 22, 2026

This AI Stock Roars To Profit, Builds Bullish Base Ahead Of This Key Catalyst

Legendary investor Peter Lynch said turnaround plays could net the biggest gains. This AI stock is looking to add to big gains and has built a bullish base.

Investors Business Daily • Feb 20, 2026

Vistance Networks to Release Fourth Quarter and Full Year 2025 Financial Results on February 26

RICHARDSON, Texas--(BUSINESS WIRE)-- #InvestorRelations--Vistance Networks (NASDAQ: VISN) plans to release fourth quarter and full year 2025 financial results on Thursday, February 26, before market open.

Business Wire • Feb 5, 2026

RUCKUS Networks Announces Expanded Pro AV ICX Switch Portfolio for Audio-Visual Over IP Networks

RICHARDSON, Texas--(BUSINESS WIRE)-- #NetworkSolutions--RUCKUS Networks, a Vistance Networks (NASDAQ: VISN) business, expanded its Pro AV ICX® network switch portfolio.

Business Wire • Feb 3, 2026

RUCKUS Networks Announces Official Partnership with TGR Haas F1 Team

RICHARDSON, Texas--(BUSINESS WIRE)-- #HaasF1Team--RUCKUS, a Vistance Networks (NASDAQ: VISN) business, announced it entered an agreement to be the Official Networking Partner of the TGR Haas F1 Team.

Business Wire • Jan 21, 2026

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children's Medical Research Institute to Develop Novel Gene Therapy Capsids

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics announces research collaboration agreement with Children's Medical Research Institute to develop novel gene therapy capsids.

Business Wire • Jun 22, 2021

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap.

Seeking Alpha • May 9, 2021

UK-based Gyroscope Therapeutics pulls Wall Street IPO due to 'unfavourable market conditions'

The news is also a blow to FTSE 250-listed Syncona, which recently upped its stake to 54%

Proactive Investors • May 7, 2021